This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill your portfolio gaps.

 

 

 

Table of Contents

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 9

1.2 List of Figures 10

2 Introduction 11

3 Biosimilars in Emerging Economies – Market Overview 12

3.1 Biosimilars 12

3.1.1 Types of Biosimilars 12

3.2 Comparison of Biosimilars with Biologics and Generics 16

3.2.1 Structural Differences between Biologics, Generics and Biosimilars 17

3.3 Development of Biosimilars 18

3.4 Manufacturing of Biosimilars 19

3.4.1 Establishing a New Biosimilar Manufacturing Facility 19

3.5 Drivers and Restraints 20

3.5.1 Drivers 20

3.5.2 Restraints 21

3.6 Top 10 Biologics in 2011 22

3.7 Patent Expiries of Leading Biologics 23

3.8 Price Comparison of Biosimilars and Reference Products 23

4 Biosimilars in Emerging Economies – Market Characterization 24

4.1 Biosimilars Market Size and Forecast for Emerging Economies 24

4.2 Major Marketed Biosimilars in Emerging Economies 25

5 Biosimilars in Emerging Economies – India 28

5.1 Biosimilars Market Overview 28

5.2 Key Market and R&D Trends 29

5.2.1 Biocon's Deal to Commercialize Biosimilar Versions of Insulin Products with Pfizer Cancelled 29

5.3 Regulatory Landscape in India 29

5.3.1 Regulatory Framework for Biosimilars 29

5.4 Challenges and Opportunities 29

5.4.1 Challenges 29

5.4.2 Opportunities 30

5.5 Key Companies 31

5.5.1 Dr. Reddy's Laboratories (DRL) 31

5.5.2 Biocon 32

5.5.3 Intas Biopharmaceuticals (IBPL) 34

5.5.4 Reliance Life Sciences 35

5.5.5 Wockhardt 37

5.5.6 Lupin 38

5.5.7 Cipla 39

6 Biosimilars in Emerging Economies – China 41

6.1 Biosimilars Market Overview 41

6.1.1 Marketed Biosimilars in China 42

6.2 Regulatory Landscape in China 42

6.2.1 Regulatory Framework for Biosimilars 42

6.3 Challenges and Opportunities 43

6.3.1 Challenges 43

3 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs